A urethral drug delivery catheter specifically designed for five-cavity prostatectomy
By designing a dedicated urethral drug injection catheter for five-cavity prostatectomy, the problems of insufficient hemostasis and incomplete bladder irrigation after prostatectomy have been solved, achieving precise hemostasis and multifunctional integrated treatment, reducing the risk of tissue damage and improving treatment outcomes.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- ZHANJIANG STAR ENTERPRISE
- Filing Date
- 2025-07-29
- Publication Date
- 2026-06-30
AI Technical Summary
Current post-prostatectomy catheters cannot achieve targeted compression hemostasis, lack urethral drug delivery channels, have limited bladder irrigation functions, and have uncontrollable balloon pressure, resulting in poor hemostasis, insufficient anti-fibrotic treatment, and a high risk of tissue damage.
A five-cavity urethral drug infusion catheter for prostatectomy has been designed, comprising a urination port, a urethral drug infusion port, a first balloon for fixation, a second balloon for urethral closure, a third balloon for wound compression, and an optional bladder irrigation cavity. It features precise hemostasis, drug infusion, and efficient bladder irrigation. The balloon pressure is controllable, and the surface of the third balloon is coated with a heparin sustained-release layer to prevent adhesion.
It achieves precise wound compression hemostasis, multifunctional integrated treatment, reduces the risk of tissue damage, improves hemostasis and long-term efficacy of anti-fibrotic treatment, and ensures operational safety.
Smart Images

Figure CN224421697U_ABST